Aura Biosciences (AURA) Stock Forecast & Price Target

Aura Biosciences is on track to meet its topline data guidance for 2H27 with the completion of enrollment for its Phase 3 CoMpass trial, a global, multi-institutional pivotal trial being conducted under an SPA agreement with the FDA for its candidate bel-sar, which has received FDA and EMA designations. Management's strategic reallocation of capital away from the NMIBC program towards the advancement of bel-sar in ocular oncology settings signals strong confidence in the potential of bel-sar's immune-driven mechanism and its potential commercial success. With a promising vision-sparing approach, clinically meaningful efficacy and durability gains, and backed by regulatory support, Aura Biosciences' stock presents a strong investment opportunity for long-term gains.

Aura Biosciences is minimizing resources towards its NMIBC program, resulting in a lowered 12-month price target of $18 based on its expectations for future revenue and expenses. However, there are still risks to achieving this target, including clinical trial failures, regulatory and commercial challenges, and competition from other companies with greater resources and potentially more effective therapies. Additionally, financial risks remain as Aura may require additional equity financing to complete development. In terms of financials, Aura reported a net loss of $25.6M for Q4 2025 and $106.2M for FY25, with R&D expenses of $21.9M and $90.3M, respectively, and slightly lower general and administrative expenses of $5.3M and $22.5M. As of December 31, 2025, Aura had cash, cash equivalents, and marketable securities of $144.2M, with a cash runway until Q1 2027.